Shattuck Labs, Inc. (STTK), a clinical-stage biotechnology company, on Wednesday revealed the pricing of its earlier announced public offering of 10.88 million shares of common stock at $4.00 per share. The company is also offering pre-funded warrants to purchase up to 7.87 million shares at $3.9999 per warrant to certain investors.
The offering is expected to generate gross proceeds of approximately $75 million before underwriting discounts, commissions, and other offering-related expenses. The transaction is expected to close on June 11, subject to customary closing conditions, the company said in an official statement.
Additionally, Shattuck Labs said that it has granted the underwriters a 30-day option to purchase up to 2.81 million additional shares of common stock at the public offering price, less underwriting discounts and commissions.
On the Nasdaq, STTK ended Tuesday's trading up 9.5 percent at $4.2700. In overnight trading, the stock was up 2.6 percent at $4.3800.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.